Adina Makover - Evogene Independent Director
| EVGN Stock | ILA 599.80 0.20 0.03% |
Director
Dr. Adina Makover as Independent Director at Evogene Ltd since February 2003. She is a member of the Compensation and Nominating committees. Dr. Makover work experience includes the following roles Director at GeneGrafts Ltd, Spine 21 Ltd, EarlySense Ltd, PerfAction Technologies Ltd, External Director at Kadimastem Ltd, Board Observer at Argo Medical Ltd and investment manager of Life Sciences ventures at ProSeed VC Fund Ltd since 2003.
| Age | 66 |
| Tenure | 21 years |
| Professional Marks | MBA |
| Phone | (972) 8 946 6724 |
| Web | www.evogene.com |
Evogene Management Efficiency
The company has return on total asset (ROA) of (0.2789) % which means that it has lost $0.2789 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.6255) %, meaning that it generated substantial loss on money invested by shareholders. Evogene's management efficiency ratios could be used to measure how well Evogene manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Yair Aharonowitz | Compugen | 73 | |
| Eran Perry | Compugen | N/A | |
| Arie Ovadia | Compugen | 67 | |
| Abraham Havron | Kamada | 71 | |
| Shmuel Rubinstein | Kamada | 78 | |
| Sanford Zweifach | Compugen | 60 | |
| Kinneret Savitsky | Compugen | 50 | |
| Jonathan Hahn | Kamada | 32 | |
| Gilead Halevy | Compugen | 51 | |
| JeanPierre Bizzari | Compugen | 64 | |
| Estery GilozRan | Kamada | 44 | |
| Ruth Arnon | Compugen | 86 | |
| Michael Berelowitz | Kamada | 74 | |
| Abraham Havron | Enlivex Therapeutics | 71 | |
| Tuvia Shoham | Kamada | 70 | |
| Gili Hart | Enlivex Therapeutics | 44 | |
| Itzhak Krinsky | Kamada | 65 | |
| Michal Preminger | Compugen | N/A | |
| Gwen Melincoff | Kamada | 67 | |
Management Performance
| Return On Equity | -0.63 | |||
| Return On Asset | -0.28 |
Evogene Leadership Team
Elected by the shareholders, the Evogene's board of directors comprises two types of representatives: Evogene inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Evogene. The board's role is to monitor Evogene's management team and ensure that shareholders' interests are well served. Evogene's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Evogene's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Mark Kapel, Executive Vice President-Technology | ||
| Martin Gerstel, Chairman of the Board | ||
| Oded Shoseyov, Director | ||
| Yaron Eldad, Chief Officer | ||
| Eyal Ronen, Exec Devel | ||
| Adina Makover, Independent Director | ||
| Adrian Percy, Director | ||
| Sarit Firon, Independent Director | ||
| Sassi Masliah, Exec Devel | ||
| Liat Wejgman, VP HR | ||
| Eran Kosover, Executive Vice President & General Manager Ag-Chemicals | ||
| Ofer CPA, CEO Pres | ||
| Ofer Haviv, President, Chief Executive Officer | ||
| Ido Dor, Executive Vice President & General Manager Ag-Biologicals | ||
| Dotan Borenstein, Chief Ltd | ||
| Nir Arbel, Chief Officer | ||
| Hagai Karchi, Chief Technology Officer & Head of R&D Ag-Biologicals | ||
| Leon Recanati, Independent Director | ||
| Alin SelaBrown, Vice President Screening & Validation Systems | ||
| Kinneret Savitsky, Independent Director | ||
| Eyal Emmanuel, Executive Vice President-R&D | ||
| Arnon Heyman, Vice President & General Manager of Ag-Seeds | ||
| Alex Taskar, Chief Financial Officer | ||
| Ziv Kop, Independent Director | ||
| Elran MBA, Chief Ltd |
Evogene Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Evogene a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.63 | |||
| Return On Asset | -0.28 | |||
| Operating Margin | (24.02) % | |||
| Current Valuation | 8.8 M | |||
| Shares Outstanding | 41.22 M | |||
| Shares Owned By Insiders | 3.58 % | |||
| Shares Owned By Institutions | 3.37 % | |||
| Price To Book | 0.93 X | |||
| Price To Sales | 73.01 X | |||
| Revenue | 930 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in Evogene Stock
When determining whether Evogene offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Evogene's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Evogene Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Evogene Stock:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evogene. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Evogene Stock refer to our How to Trade Evogene Stock guide.You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.